This is Dae-jin Kim,
CEO of Digital Pharm.

I am the President of the Information Convergence Institute, which oversees the IT of the Catholic Medical Center.
As a psychiatrist at Seoul St. Mary's Hospital, I am treating alcohol, nicotine and drug/behavior addiction, depression, etc. Digital Pharm is specialized in digital therapeutics(DTx) and electroceuticals. Digital Pharm is a subsidiary company of the Technology Holding company at The Catholic University of Korea, and received a strategic joint investment from KT and Hanmi Pharmaceutical last June.
Through the combination of 3-party system, we strive to maximize mutual synergy by sharing roles in focusing areas where we can secure high competitiveness in each business .

Currently, we are focusing on various clinical trials and business model development through the pipeline we have just developed.
When the primary goal is established, we will provide a digital treatment device platform with high user convenience through platform configuration. If a patient can conveniently receive treatment with a smartphone or smart TV at home using a digital treatment device prescribed by a doctor, it will increase the effectiveness for elderly patients with poor medical access or those who have significant time and financial burden and mobility difficulties.
In addition, it is expected that the treatment effect can be maximized with customized prescription using lifelog.